Overcome the Impairment of NK Cells for Icon and Antibody Immunotherapy of Cancer

Natural killer (NK) cells play an important role in innate immunity and in mediating antibody and Icon (an antibody-like factor VII/IgG1 Fc immunoconjugate, which, to our best knowledge, was the first therapeutic agent for dual targeting of both the tumor cells and tumor angiogenic endothelial cells) for cancer immunotherapy. However, a common yet often neglected observation and challenge in antibody immunotherapy is that NK cells are often impaired in cancer patients. Here we hypothesize that the impairment of NK cells significantly contributes to host resistance to antibody immunotherapy for cancer. In order for antibody and Icon to achieve their optimal therapeutic efficacy, we briefly reviewed the current strategies to enhance NK activity, including infusion of cytokines, vaccines or NK cells, and the use of dietary supplements. Moreover, from our point of view we identified some remaining challenges and propose to combine these NK-enhancing strategies with Icon or antibody to overcome NK impairment and ultimately to optimize the efficacy of Icon and antibody immunotherapy for cancer.


Introduction
Natural killer (NK) cells are a class of lymphocytes distinct from T-and B-cells and play an important role in the innate immune system for direct killing of virusinfected cells and cancer cells as well as in antibodymediated killing in antibody immunotherapy of cancer [1,2].NK cells are large granular lymphocytes lacking of CD3 and T cell receptors and compose about 10% -20% of peripheral blood lymphocytes in healthy individuals [1,3,4].They commonly express certain cell surface markers such as CD16 and CD56 in humans and NK-1.1/NK-2.1 and CD49b in mice for identification and isolation of NK cells.CD56+ and CD3− can be used as distinct surface markers for identification of human NK cells, whereas CD16 is the receptor for the Fc portion of immunoglobulin gamma (IgG Fc) (FcRIII receptors) to mediate antibody-dependent cell-mediated cytotoxicity (ADCC).In addition, NK cells can produce a variety of cytokines [5], e.g., interleukin-1 (IL-1), IL-2, IL-4, IL-12, IL-15, interferons (IFN), tumor necrotic factors (TNF- and ), etc.These NK-producing cytokines have numerous widespread actions including direct anti-tumor effects and autochthonous NK regulation.

Antibody and Icon Immunotherapy for Cancer
In the past decades, effects have been focused on identi-fication of target antigens on one of two major tumor compartments, either tumor cells or tumor neovasculature, and subsequently several therapeutic chimeric or completely humanized antibodies have been developed against common growth factors or their receptors [6], such as epidermal growth factors HER-1 (Cetuximab), HER-2/neu (Trastuzumab), or angiogenic growth factors, such as vascular endothelial growth factor (VEGF) (Bevacizumab), for cancer immunotherapy.We proposed that simultaneous targeting of both the tumor compartments, i.e., tumor cells and tumor neovasculature, could achieve better therapeutic effect than targeting of tumor cells or tumor neovasculature alone [7].In this regard, we constructed in 1999 the first dual neovascular-and tumor cell-targeting antibody-like factor VII/IgG1 Fc immunoconjugate molecule [8], later called an Icon [9,10] (Figure 1).The Icon is composed of two mature factor VII (fVII) polypeptides with a mutation of Lys341Ala (K341A) fused to the Fc domain of a human IgG1 antibody by recombinant DNA technology [8][9][10][11].The reason for introducing Alanine mutation to Lysine 341 in fVII protein was to reduce its coagulation activity while its binding activity to TF retains [10].The Icon molecule is designed to bind to tissue factor (TF), a common yet specific target molecule on tumor angiogenic endothelial cells (but not on normal resting vascular endothelial cells) and many types of cancer cells [8,10,12], with far higher affinity and specificity than can be achieved with an anti-TF antibody.We tested the efficacy and safety of Icon immunotherapy for cancer in several mouse models of primary and metastatic mouse and human cancer [9,10,13], including melanoma [8,9], prostate [10], breast [13], tongue [11] and endometrial [14] cancer.The results of these extensive tests demonstrated that the Icon immunotherapy eradicated primary and disseminated metastatic tumors without associated toxicity [8-11, 13,14].In addition for cancer treatment, we and our collaborators also showed that Icon immunotherapy could eradicate choroidal neovasculature in mouse and pig models simulating the wet form of age-related macular degeneration [15,16], as either intravenous or intraocular injections with Icon protein or encoded in replicationincompetent adenoviral vector, and that Icon protein eradicated human endometriosis in a nude mouse model [17].

Crucial Role of NK Cells in Icon and Antibody Immunotherapy of Cancer
NK cells play two distinct roles in cancer immunotherapy, the first being to prevent tumor development by direct killing as innate immune cells and the other to mediate ADCC by antibody or Icon-guided specific killing after antibody or Icon immunotherapy is initiated [11].We recently reported for the first time that NK cells are crucial for the efficacy of Icon immunotherapy for human cancer in preclinical mouse models [11].Previous reports also showed that NK cells could mediate ADCC for other therapeutic antibodies including Trastuzumab (Herceptin) for breast cancer [18], Rituximab (Rituxan) for B-cell lymphoma [19], and Cetuximab for lung cancer [20].Thus NK cells play important, or even crucial, role in Icon and antibody immunotherapy for cancer.

Impairment of NK Cells in Cancer Patients
A major challenge, yet often neglected, in antibody immunotherapy is the impairment of NK cells in cancer patients, which could be responsible for host resistance to antibody immunotherapy.A few years after the discovery of NK cells [21][22][23], it was found that NK cells could be impaired, observed as lower level/decreased activity in peripheral blood lymphocytes (PBL), by tumors in animals and cancer patients [24].In later years, more reports showed that the ADCC activity of NK cells was impaired in patients with cancer [1,25,26], including head and neck [27,28], breast [29], gastric [30], esophageal [31,32], cervical [33] and urologic cancers [34] as well as leukemia [35][36][37] and myeloma [38].In addition, NK activity could decline with age [39], which may contribute to and explain why higher incidence of cancer developed in elderly populations.With regard to the role of NK cells in Icon immunotherapy for cancer, we observed in a recent study [11] that Icon immunotherapy was able to completely eradicate human tongue tumor xenografts in the CB-17 strain of SCID mice that have functional and normal levels of NK cells [40], but not in the Beige strain of SCID mice that have defective NK cells [41,42].Icon was also unable to completely eradicate human tongue tumor xenografts in some of the partially responded CB-17/SCID mice, in which NK cell percentages (3.7% ± 0.9%) of PBL were lower than the normal average (16% of PBL) [11].Since both SCID strains are deficient of T-and B-cells [40,41], we concluded that impairment of NK cells significantly contributed to host resistance to Icon or antibody immunotherapy for cancer [11].Implication of resistance to antibody has also been observed in clinical trials.For example, there were 66% -88% of patients with metastatic breast cancer with resistance to single agent Her2-targeted trastuzumab immunotherapy even though the cancer cells overexpressed the Her2 antigen [43].To find out the factors causing the resistance, Varchetta et al., analysed circulating mononuclear cells in 18 breast cancer patients after Her2 targeted-trastuzumab therapy and concluded that quantity and lytic efficiency of CD16+ NK cells are major factors for the effectiveness of trastuzumab immunotherapy [44].The mechanism of impairment of NK cells by cancer cell remains to be investigated.Taken together, these findings suggest that impairment of NK level/activity contributes to resistance to Icon and other therapeutic antibodies that are currently under investigation in preclinical and clinical studies.However, both methods currently have their limitations.With cancer cell vaccine, these whole-cell vaccines as single agent therapy did not show efficacy in several Phase III clinical trials [54].With cytokines, they are limited because cytokines as protein molecules with short half-life have to be administered repeatedly in vivo and are therefore associated with significant toxicity at high dose [55,56] or with uncertain efficacy at lower doses [57].Infusions of autologous or allogeneic NK cells for cancer therapy have been shown feasible and well-tolerated in cancer patients [58][59][60].Although it was safe, efficacy of clinical trials with infusion of autologous NK cells shows no effect [61].Similarly, Dr. Rosenberg's group at the National Cancer Institute of NIH recently reported that adoptive transfer of autologous NK cells as single agent therapy could maintain high levels of circulating NK cells in patients but did not mediate tumor regression [62].With allogeneic NK cells, the limitations are that other peripheral blood lymphocytes are always contaminated in the final NK products even under Good Manufacture Production (GMP) [63] and those NK cells from donors likely differ in killing activity from individual to individual [5].

Remaining Challenges
To overcome the limitations of current efforts on enhancing NK activity and to achieve an optimal therapeutic efficacy for cancer patients, we propose to synergistically combine antibody or Icon with these NK-stimulating strategies (the use of biologic agents, NK cells and/or dietary supplement) for cancer immunotherapy.
In order to evaluate NK activity/level among cancer patients with antibody and Icon immunotherapy, it would be ideal and helpful to use common NK lines as standard NK effector cells and common NK activity/level assays, which remain to be developed.Therefore, from our point of view we believe that other remaining challenges in antibody immunotherapy are as follows: 1) to develop immortalized NK cell lines with ability to mediate antibody ADCC function as standard NK cell line for comparing and determining cancer patient's NK activity; 2) to develop a more convenient method, ideally, to measure both the NK cell level (percent and/or actual number of NK cells in peripheral blood lymphocytes) and activity (function) for routine use in clinical laboratories.
Regarding immortalized NK lines, there are a few studies on generation of murine NK [85][86][87][88][89] and human NK [90] cell lines.Dr. Tian and coworkers recently summarized the NK cell lines in cancer immunotherapy [48].However, it was unclear if those NK cell lines were able to mediate ADCC.Moreover, many of them are not publicly available, for example, from ATCC.To our best knowledge, the only two human NK lines available at ATCC are NK-92 (IL-2 dependent) and NK-92MI (IL-2 independent) [91,92].But they were derived from a patient with lymphoma and do not express CD16, and therefore they cannot mediate ADCC.
Currently NK activity in ADCC has been mainly determined by the radioactive isotope Chromium-51 ( 51 Cr) release assay, in which target cells (e.g., cancer cells) are first dissociated and then labeled with 51 Cr sequentially followed by incubation with test antibody and then with PBL or isolated NK cells.To avoid the use of radio-isotope and dissociation of target cells, our group [11] and others [93] have used non-radioisotope assays, in which the target cancer cells are labeled in the wells of mcroas-say plates with fluorescent dyes (e.g., Calcein AM).To measure mouse NK level in PBL, we recently established a flow cytometry protocol using fluorescent dye-conjugated anti-mouse CD49b (clone DX5) [11].Since CD49b is expressed by the majority of NK cells (and a small Tcell subpopulation) in most mouse strains [94], this flow cytometry procedure for mouse NK level could be broadly used in mouse studies.Similarly, a flow cytometry using anti-human NK cell markers such as CD16 and CD56 could be easily established for measuring human NK level.To our best knowledge, there is no established method yet for determining the actual number of NK cells in PBL.We believe that monitoring NK level (percent and/ or the actual number in PBL) and activity is important because it could help better design and optimize preclinical and clinical trials of antibody and Icon immunotherapy, particularly in combination with NK-enhancing treatment.

Concluding Remarks
In our opinion, the impairment of NK cells is a common yet often neglected challenge in antibody immunotherapy of cancer.To bring this attention to the field and even to more general readers, we briefly reviewed the current strategies and efforts on enhancing NK activity, including infusion of cytokines, vaccines, NK cells and/or the use of dietary supplements.The latter has been more extensively reviewed by Dr. Thornthwaite and co-workers [23] and by many others, as discussed above.Furthermore, we discussed the limitations of these current strategies, identified some remaining challenges and proposed to develop immortalized effector NK lines and NK level/activity assays as common standards for future clinical trials and applications of Icon and antibody immunotherapy.Moreover, we proposed to combine these biologic agents, NK cells and/or dietary supplements with antibody or Icon immunotherapy in order to overcome the NK impairment, and ultimately, to achieve the optimal efficacy and clinical outcome of Icon and antibody for cancer immunotherapy.